1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Luye Pharma Group Ltd.

Luye Pharma Group Ltd.

1.58
HKD
-0.11
(-6.78%)
10.94BMarket Cap
Mar 31Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.1
0.85
0.77
0.88
1.17
1.61
1.98
1.74
1.51
1.72
1.65
1.61
1.62
- -
Basic EPS, GAAP
0.63
0.2
0.23
0.27
0.3
0.41
0.44
0.22
-0.04
0.17
0.14
0.13
0.16
- -
Free Cash Flow per Basic Share
0.34
0.07
0.06
0.08
0.1
-0.45
-0.51
-0.15
-0.39
0.14
0.12
-0.41
0.2
- -
Dividend per Share
- -
- -
- -
0.03
0.07
0.09
0.12
0.06
- -
- -
- -
- -
- -
- -
Book Value per Share
0.53
1.48
1.71
1.94
2.11
2.38
2.82
2.52
2.48
2.96
3.33
3.76
4.02
4.02
Tangible Book Value per Share
0.39
1.33
1.56
1.38
1.53
0.71
1.01
0.66
0.6
0.93
1.37
1.74
2.06
2.06
Basic Weighted Avg Shares
493
2,995
3,321
3,321
3,258
3,208
3,203
3,187
3,445
3,481
3,728
3,762
3,896
3,878
Sales/Revenue/Turnover
2,515
2,544
2,563
2,918
3,815
5,173
6,358
5,540
5,200
5,982
6,143
6,061
6,308
- -
Operating Margin (%)
16.45
28.49
32.42
31.35
28.59
29.32
27.37
21.94
5.44
15.95
16.75
21.3
19.9
- -
Depreciation Expense
100
110
115
141
250
317
456
511
582
671
702
791
839
- -
Net Income, GAAP
310
606
755
892
981
1,303
1,396
707
-134
605
533
472
619
- -
Effective Tax Rate (%)
14.41
15.31
14.86
8.28
12.16
11.37
17.13
25.36
- -
12.91
23
23.14
25.3
- -
Profit Margin (%)
12.35
23.8
29.44
30.56
25.73
25.19
21.96
12.76
-2.58
10.11
8.67
7.79
9.81
- -
Working Capital
349
2,638
4,026
2,908
2,641
472
3,819
2,736
3,066
1,299
2,565
2,539
5,297
5,297
LT Debt
9
1
- -
- -
- -
848
4,510
4,339
4,228
2,265
3,228
2,736
2,723
2,723
Total Equity
1,898
5,038
5,800
6,562
6,896
7,934
8,920
8,099
9,114
11,042
13,528
15,754
18,359
18,359
Return on Invested Capital (%)
15.01
15.79
15.76
14.85
10.35
11.02
9.01
4.91
- -
4.11
3.74
4.1
3.41
- -
Return on Capital (%)
13.92
15.78
13.01
12.66
11.44
12.19
10.67
5.77
- -
5.35
4.97
3.04
3.88
- -
Return on Common Equity (%)
20.39
18.14
14.27
14.75
14.87
17.88
16.7
8.41
-1.64
6.48
4.69
3.54
4.09
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
7,585
8,721
6,694
LT Borrowings
2,694
3,112
2,688
LT Finance Leases
42
37
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,762
3,762
3,995
Market Capitalization
7,670
12,290
9,835

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
13,308
15,687
15,233
Cash, Cash Equivalents & STI
6,503
8,833
7,495
Accounts Receivable, Net
2,384
2,886
2,847
Inventories
912
872
957
Total Current Liabilities
10,769
11,939
9,936
Payables & Accruals
- -
- -
- -
ST Debt
7,585
8,721
6,694
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.57%
17.84%
16.54%
Free Cash Flow
-108.87%
-115.52%
-150.65%
Net Income, GAAP
-64.25%
-132.25%
31.12%
Sales/Revenue/Turnover
10.46%
2.87%
4.07%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
6,143
2024
- -
- -
6,061
2025
- -
- -
6,308

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.14
2024
- -
- -
0.13
2025
- -
- -
0.16

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dian Bo Liu
Full Time Employees
5,221
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 15 Chuang Ye Road Guangzhou GD China 264003
IPO Date
Jul 9, 2014
Website
luye.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Luye Pharma Group Ltd. Luye Pharma Group Ltd. (2186.HK) is an investment holding company engaged in the research, development, manufacturing, marketing, and sale of innovative pharmaceutical products with a focus on novel drug delivery systems including microspheres, liposomes, and transdermal patches; it also develops new chemical entities and antibody drugs across core therapeutic areas such as central nervous system disorders (including schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease psychosis, Parkinson's disease psychosis, and negative schizophrenia symptoms with products like Erzofri (paliperidone palmitate) extended-release injectable suspension, Rykindo (risperidone) extended-release injectable suspension, Ruoxinlin (toludesvenlafaxine hydrochloride sustained-release tablets), Rivastigmine Twice Weekly Transdermal Patch, Jinyouping (rotigotine microspheres for injection), and rotigotine transdermal patch), oncology, cardiovascular, alimentary tract and metabolism, as well as other segments; the company operates over 30 launched products and maintains a pipeline of more than 30 investigational candidates including small-molecule drugs like LY03017 (next-generation 5-HT2AR inverse agonist/5-HT2CR antagonist), LY03015 (VMAT2/Sigma-1R), LY03020 (TAAR1/5-HT2CR), and LY03021 (NET/DAT/GABAAR). Founded in 1994 and headquartered in Yantai, China, with key R&D centers in China, the U.S., and Europe, plus eight GMP-compliant manufacturing facilities worldwide, Luye Pharma conducts business in over 80 countries and regions encompassing major markets like China, the U.S., Europe, and Japan, alongside emerging markets in Asia, Latin America, Africa, and Oceania. Recent developments include FDA clearance in November 2025 for the IND of LY03017 to advance directly to multiple ascending dose trials for Alzheimer's and Parkinson's disease psychosis and negative schizophrenia symptoms; enrollment completion for the Phase III trial of Ruoxinlin for generalized anxiety disorder in August 2025 and first subject dosing in a Phase I trial for LY03021 in China; launch of rotigotine transdermal patch in the UK in April 2025; acquisition of Acino's transdermal patch business in June 2025 to bolster R&D and manufacturing; a July 2024 investment agreement to upgrade oncology R&D through collaborations; and reporting 32% growth in new product sales alongside an upgraded international strategy emphasizing in-house development plus business development partnerships in its 2025 half-year results.